HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BDA-366

has antineoplastic activity; binds Bcl-2 protein; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Deng, Xingming: 2 articles (05/2016 - 06/2015)
2.	Park, Dongkyoo: 2 articles (05/2016 - 06/2015)
3.	Andrews, David W: 1 article (01/2020)
4.	Bultynck, Geert: 1 article (01/2020)
5.	Chakraborty, Supriya: 1 article (01/2020)
6.	Economou, Anastassios: 1 article (01/2020)
7.	Efremov, Dimitar G: 1 article (01/2020)
8.	Kale, Justin: 1 article (01/2020)
9.	Karamanou, Spyridoula: 1 article (01/2020)
10.	La Rovere, Rita M: 1 article (01/2020)

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 06/08/2015 - "BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. " 01/01/2020 - "Recently, BDA-366 was identified as a small molecule BH4-domain antagonist that could kill lung cancer and multiple myeloma cells. " 06/08/2015 - "Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo. "
2.	Neoplasms (Cancer) 01/01/2020 - "BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models."
3.	Multiple Myeloma 01/01/2020 - "Recently, BDA-366 was identified as a small molecule BH4-domain antagonist that could kill lung cancer and multiple myeloma cells. "
4.	Body Weight (Weight, Body) 05/10/2016 - "Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγnull mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. "

Related Drugs and Biologics

1.	Everolimus